Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF), which is developing immunotherapies for cancer and infectious diseases, has announced the immediate appointment of Dr Mandeep Sehmi as its head of business development.
With over a decade of experience in the business development sector of biotechnology, her resume includes roles at Abcam (AIM:ABC), where she oversaw the cancer and metabolism portfolios, and Cancer Research Technology, with a focus on antibody out-licensing.
At Isogenica, she played a pivotal role in striking deals for their antibody platform, including a significant agreement with BioNTech.
Immediately prior to joining Scancell, Sehmi served as the director of business development at ImaginAb, where she spearheaded out-licensing opportunities in immuno-oncology.
She holds a PhD in cell and molecular biology and a Master's in molecular pathology and toxicology.
"The appointment of Mandeep is an exciting development for Scancell as we continue to expand our commercial capabilities," said professor Lindy Durrant, Scancell's chief executive.
"As communicated at the time of the recent business update, our strategic focus is on the continued development of the company's two lead clinical assets SCIB1 and Modi-1.
"The value of our antibody platform, however, remains a powerful asset in enabling us to generate revenue through high-value licence agreements and Mandeep, with her extensive network and business development experience in the antibody sector, will be invaluable as the company continues to pursue attractive commercialisation avenues for our therapeutic assets."